Rainer H. Böger mostly deals with Internal medicine, Endocrinology, Asymmetric dimethylarginine, Nitric oxide and Endothelium. He works mostly in the field of Internal medicine, limiting it down to concerns involving Diabetes mellitus and, occasionally, Heart failure. His Endocrinology research incorporates elements of Inflammation and Stroke.
His biological study spans a wide range of topics, including Chromatography, Endogeny, End stage renal disease and Risk factor. His Nitric oxide research integrates issues from Biochemistry, Vascular disease and Citrulline. His research in Endothelium intersects with topics in Endothelial stem cell, Disease and Cell biology.
Rainer H. Böger mainly investigates Internal medicine, Endocrinology, Asymmetric dimethylarginine, Nitric oxide and Cardiology. His Internal medicine research focuses on Diabetes mellitus and how it relates to Body mass index. His work on Endocrinology is being expanded to include thematically relevant topics such as Disease.
His studies in Asymmetric dimethylarginine integrate themes in fields like Heart failure, Endogeny, Pharmacology, Cohort and Risk factor. The various areas that he examines in his Nitric oxide study include Hypoxia, Vasodilation, Biochemistry, Pulmonary hypertension and Citrulline. The Cardiology study combines topics in areas such as Hazard ratio and Confidence interval.
His primary areas of investigation include Internal medicine, Asymmetric dimethylarginine, Endocrinology, Cardiology and Nitric oxide. The study of Internal medicine is intertwined with the study of Gastroenterology in a number of ways. His research integrates issues of Nitric oxide synthase, Hypoxia, Pulmonary hypertension, Pathophysiology and Vasodilation in his study of Asymmetric dimethylarginine.
His work carried out in the field of Endocrinology brings together such families of science as Intima-media thickness and Arginase. Endothelium and Adverse effect is closely connected to Prospective cohort study in his research, which is encompassed under the umbrella topic of Cardiology. His Nitric oxide research includes themes of Inflammation and Sepsis.
Rainer H. Böger spends much of his time researching Internal medicine, Asymmetric dimethylarginine, Endocrinology, Nitric oxide and Cardiology. In Internal medicine, Rainer H. Böger works on issues like Surgery, which are connected to Peripheral blood mononuclear cell and Severity of illness. His Asymmetric dimethylarginine study combines topics from a wide range of disciplines, such as Hypoxia, Pulmonary hypertension, Effects of high altitude on humans, Pathophysiology and Vasodilation.
His work on Nitric oxide synthase, Kidney disease and Omega-N-Methylarginine as part of general Endocrinology research is frequently linked to Percentile, bridging the gap between disciplines. Rainer H. Böger combines subjects such as Sepsis, Ventricular hypertrophy, Cardiac function curve, Fibrosis and Muscle hypertrophy with his study of Nitric oxide. His Cardiology research is multidisciplinary, incorporating perspectives in Prospective cohort study, Cerebrospinal fluid and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction Its Role in Hypercholesterolemia
Rainer H. Böger;Stefanie M. Bode-Böger;Andrzej Szuba;Philip S. Tsao.
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study
Carmine Zoccali;Stefanie M Bode-Böger;Francesca Mallamaci;Frank Antonio Benedetto.
The Lancet (2001)
Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)
Joseph Pergolizzi;Rainer H. Böger;Keith Budd;Albert Dahan.
Pain Practice (2008)
Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
Jan T. Kielstein;Rainer H. Böger;Stefanine M. Bode-Böger;Jürgen Schäffer.
Journal of The American Society of Nephrology (1999)
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
Rainer H Böger.
Cardiovascular Research (2003)
Marked Increase of Asymmetric Dimethylarginine in Patients with Incipient Primary Chronic Renal Disease
Jan T. Kielstein;Rainer H. Böger;Stefanie M. Bode-Böger;Jürgen C. Frölich.
Journal of The American Society of Nephrology (2002)
Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease
Carmine Zoccali;Francesco Antonio Benedetto;Renke Maas;Francesca Mallamaci.
Journal of The American Society of Nephrology (2002)
Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism.
Edzard Schwedhelm;Renke Maas;Ralf Freese;Donald Jung.
British Journal of Clinical Pharmacology (2008)
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Latika Sibal;Sharad C Agarwal;Philip D Home;Rainer H Boger.
Current Cardiology Reviews (2010)
Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay.
Friedrich Schulze;Reinhard Wesemann;Edzard Schwedhelm;Karsten Sydow.
Clinical Chemistry and Laboratory Medicine (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: